Abstract
The proteins Ure2, Sup35 and Rnq1 from the bakers yeast have infectious properties, termed prions, at the origin of heritable and transmissible phenotypic changes. It is widely believed that prion properties arise from the assembly of Ure2p, Sup35p and Rnq1p into insoluble fibrils. Yeast prions possess regions crucial for their propagation that can be either N- or C-terminal. These regions have unusual amino acid composition. They are very rich in glutamine and asparagine residues and resemble in that to huntingtin, a protein involved in the neurodegenerative Huntingtons disease. Yeast prions assembly process has been hypothesized to be the consequence of the properties of glutamines and asparagines to engage in polar protein-protein interactions, termed polar-zippers. While this can certainly occur under certain conditions, glutamine and asparagine residues can establish other kinds of interactions with a variety of amino acid residues thus mediating protein-protein interactions involved in the assembly of polypeptide chains into high molecular weight oligomers. This review details the interactions that can be established by glutamine and asparagine residues that may allow a better understanding of their role in mediating protein-protein interactions and prion propagation.
Keywords: Prion, [PSI+], [URE3], Sup35p, Ure2p, amyloid fibrils, native-like assemblies
Current Alzheimer Research
Title: Assembly of the Asparagine- and Glutamine-Rich Yeast Prions into Protein Fibrils
Volume: 5 Issue: 3
Author(s): Luc Bousset, Jimmy Savistchenko and Ronald Melki
Affiliation:
Keywords: Prion, [PSI+], [URE3], Sup35p, Ure2p, amyloid fibrils, native-like assemblies
Abstract: The proteins Ure2, Sup35 and Rnq1 from the bakers yeast have infectious properties, termed prions, at the origin of heritable and transmissible phenotypic changes. It is widely believed that prion properties arise from the assembly of Ure2p, Sup35p and Rnq1p into insoluble fibrils. Yeast prions possess regions crucial for their propagation that can be either N- or C-terminal. These regions have unusual amino acid composition. They are very rich in glutamine and asparagine residues and resemble in that to huntingtin, a protein involved in the neurodegenerative Huntingtons disease. Yeast prions assembly process has been hypothesized to be the consequence of the properties of glutamines and asparagines to engage in polar protein-protein interactions, termed polar-zippers. While this can certainly occur under certain conditions, glutamine and asparagine residues can establish other kinds of interactions with a variety of amino acid residues thus mediating protein-protein interactions involved in the assembly of polypeptide chains into high molecular weight oligomers. This review details the interactions that can be established by glutamine and asparagine residues that may allow a better understanding of their role in mediating protein-protein interactions and prion propagation.
Export Options
About this article
Cite this article as:
Bousset Luc, Savistchenko Jimmy and Melki Ronald, Assembly of the Asparagine- and Glutamine-Rich Yeast Prions into Protein Fibrils, Current Alzheimer Research 2008; 5 (3) . https://dx.doi.org/10.2174/156720508784533303
DOI https://dx.doi.org/10.2174/156720508784533303 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetic Concepts Revisited - Basic and Applied
Current Pharmaceutical Biotechnology Crystal Structure and Interaction of Phycocyanin with β-Secretase: A Putative Therapy for Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Use of Antiepileptic Drugs for Hyperkinetic Movement Disorders
Current Neuropharmacology Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction
Current Pharmaceutical Design Spinacia oleracea Linn Considered as One of the Most Perfect Foods: A Pharmacological and Phytochemical Review
Mini-Reviews in Medicinal Chemistry Cytokine Polymorphisms in Chronic Inflammatory Diseases with Reference to Occupational Diseases
Current Molecular Medicine Neuroimaging Outcomes in Studies of Cognitive Training in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review
Current Pharmaceutical Design Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Recent Development in [1,4]Benzodiazepines as Potent Anticancer Agents: A Review
Mini-Reviews in Medicinal Chemistry Virulence Factors of Helicobacter pylori: Practical Biomarkers
Recent Patents on Biomarkers The Risk That DSM-5 Will Give Personality Dimensions A Bad Name
Current Psychiatry Reviews Possible Involvement of N-methyl-D-aspartate Receptor (NMDA-R) in the Antidepressant- like Effect of Trigonelline in Male Mice
Current Pharmaceutical Design A Review on Deep Learning Architecture and Methods for MRI Brain Tumour Segmentation
Current Medical Imaging Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem
Current Neuropharmacology Tau PET Distributional Pattern in AD Patients with Visuospatial Dysfunction
Current Alzheimer Research A New Regulatory Road-Map for Alzheimer’s Disease Drug Development
Current Alzheimer Research